239 related articles for article (PubMed ID: 27528054)
21. Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy.
Cheng W; Zhou J; Tian X; Zhang X
Curr Med Chem; 2016; 23(29):3343-3359. PubMed ID: 27160532
[TBL] [Abstract][Full Text] [Related]
22. Recent progress of small molecular VEGFR inhibitors as anticancer agents.
Xu D; Wang TL; Sun LP; You QD
Mini Rev Med Chem; 2011 Jan; 11(1):18-31. PubMed ID: 21034401
[TBL] [Abstract][Full Text] [Related]
23. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular toxicity of new agents.
Maitland ML
Clin Adv Hematol Oncol; 2008 Sep; 6(9):657-9. PubMed ID: 18827788
[No Abstract] [Full Text] [Related]
25. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
26. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.
Winder T; Lenz HJ
Gastroenterology; 2010 Jun; 138(6):2163-76. PubMed ID: 20420953
[TBL] [Abstract][Full Text] [Related]
28. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Mar; 129():65-83. PubMed ID: 29408302
[TBL] [Abstract][Full Text] [Related]
29. [Tyrosine kinase inhibitors].
Robert J
Bull Cancer; 2011 Nov; 98(11):1321-34. PubMed ID: 22023787
[TBL] [Abstract][Full Text] [Related]
30. Emerging targeted therapies for breast cancer.
Alvarez RH; Valero V; Hortobagyi GN
J Clin Oncol; 2010 Jul; 28(20):3366-79. PubMed ID: 20530283
[TBL] [Abstract][Full Text] [Related]
31. Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma.
Reuter CW; Morgan MA; Grünwald V; Herrmann TR; Burchardt M; Ganser A
World J Urol; 2007 Mar; 25(1):59-72. PubMed ID: 17340158
[TBL] [Abstract][Full Text] [Related]
32. Response to sunitinib malate in advanced alveolar soft part sarcoma.
Stacchiotti S; Tamborini E; Marrari A; Brich S; Rota SA; Orsenigo M; Crippa F; Morosi C; Gronchi A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2009 Feb; 15(3):1096-104. PubMed ID: 19188185
[TBL] [Abstract][Full Text] [Related]
33. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
34. Benzimidazole-based protein kinase inhibitors: Current perspectives in targeted cancer therapy.
Ali AM; Tawfik SS; Mostafa AS; Massoud MAM
Chem Biol Drug Des; 2022 Nov; 100(5):656-673. PubMed ID: 35962624
[TBL] [Abstract][Full Text] [Related]
35. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
36. Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.
Furge KA; MacKeigan JP; Teh BT
Lancet Oncol; 2010 Jun; 11(6):571-8. PubMed ID: 20381423
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of platelet-derived growth factor receptor tyrosine kinase and downstream signaling pathways by Compound C.
Kwon HJ; Kim GE; Lee YT; Jeong MS; Kang I; Yang D; Yeo EJ
Cell Signal; 2013 Apr; 25(4):883-97. PubMed ID: 23277201
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
39. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
40. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
